Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma

BACKGROUND: Lung squamous cell carcinoma (LUSC) is a highly malignant tumor with an extremely poor prognosis. Immune checkpoint inhibitors (ICIs) improve survival in some patients with LUSC. Tumor mutation burden (TMB) is a useful biomarker to predict the efficacy of ICIs. However, predictive and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yuting, Xu, Min, Zhao, Kai, Liu, Baodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089836/
https://www.ncbi.nlm.nih.gov/pubmed/37065576
http://dx.doi.org/10.21037/jtd-23-103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089836/
https://www.ncbi.nlm.nih.gov/pubmed/37065576
http://dx.doi.org/10.21037/jtd-23-103

Ejemplares similares